Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

Citations Over TimeTop 14% of 2011 papers

Abstract

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

Related Papers

• → Effect of retinol on iron bioavailability from Iranian bread in a Caco-2 cell culture model(2006)20 cited
• → Dissolution Systems for Chloramphenicol Tablet Bioavailability(1979)15 cited
• → Bioavailability of cyclandelate from capsules in beagle dogs and dissolution rate: Correlations with bioavailability in humans.(1991)5 cited
• → Study of the bioavailability of different formulations of 8‐methoxypsoralen in the dog(1988)4 cited
• → Prediction of Bioavailability(2003)2 cited